Not trying to say they are not bringing in alot of revenues but just because some of their customers are big, Nasdaq/NYSE corporations does not necessarily mean they have huge revenues. I work at a small biotech company and some of our customers include Arqule ($3.50 Nasdaq stock), Seattle Genetics ($10.25 Nasdaq stock), Genzyme ($55 Nasdaq stock), Amgen ($57 Nasdaq stock), Yale, Harvard, and more. Yet our revenues are only about $300-350,000 per year. In case I missed it, has anyone (probably would have been Me2) ever found out the cost of some of their services?